- امروز : یکشنبه, ۲۷ آبان , ۱۴۰۳
- برابر با : Sunday - 17 November - 2024
اخبار ویژه
Silent Damage First: Alzheimer’s Disease Could Have Two Phases
Sports Concussion Outcomes Can Be Made Worse By Depression
Dad’s Use of Diabetes Med Metformin Won’t Raise Birth Defect Risk
Fitness, Activity Boosts Kids’ Mental Health, Too
Exercise in Pregnancy Might Lower Baby’s Odds for Asthma Later
Some IUDs May Raise The Odds for Breast Cancer, But Overall Risk Remains Low
Music Might Speed Your Recovery From Surgery
A Cancer Diagnosis Takes Devastating Toll on Family Finances
Obesity
Moving Off the Couch Brings Healthy Aging: Study Finds Benefit
It's tempting to binge-watch TV, but yet another study finds that when it comes to healthy aging, the less time on your sofa, the better.
Adult High Blood Pressure Could Begin in Childhood
The seeds of high blood pressure in adulthood might be sown in youth, a new study suggests.
Obesity in Childhood Doubles Odds for MS in Young Adulthood
Children who are obese face double the odds of developing multiple sclerosis later in life, a new study warns.
Could New Weight-Loss Drugs Be Changing Women’s Taste for Sweets?
Ozempic and Wegovy appear to improve people’s sensitivity to tastes, potentially lowering their desire for sweets, a new study suggests.
Nerve Zap Treatment for Sleep Apnea Less Effective in Obese People
Obese folks are less likely to benefit from a nerve-stimulation treatment for sleep apnea that’s recently been made available to them, a new study reports.
Ozempic Lowers Odds for Death, Illness in People With Kidney Disease and Type 2 Diabetes
Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found.
Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds
Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than a third have stopped, new research shows.
Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans
The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report finds.
